RxDoctor Payments Data

Lauren Misuraca

Family · West Babylon, NYNPI 1639612815

Payments from drug & device makers

$2,287in general payments, 2019–2025

Across 111 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$734
  • Novo Nordisk$296
  • Abbott$202
  • Pfizer$187
  • Exact Sciences$133
  • Daiichi Sankyo Inc.$111
  • plus $625 from 15 others

What the payments were for

  • Food & beverage$2,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,287 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$109,211
Medicare patients
188
Services billed
3,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$38,608
MounjaroTirzepatide19$31,860
Tresiba Flextouch U-200Insulin Degludec17$23,624
EliquisApixaban19$21,192
JardianceEmpagliflozin18$20,664
FarxigaDapagliflozin Propanediol17$17,363
MyrbetriqMirabegron11$14,593
Fenofibrate12$5,883
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,518
Nebivolol Hcl32$3,191
Verapamil SrVerapamil Hcl12$2,974
Albuterol Sulfate HfaAlbuterol Sulfate63$2,666
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df18$2,120
Metoprolol Succinate102$1,672
SynthroidLevothyroxine Sodium15$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$38,60820 claims
Lilly USA, LLCMounjaro$55$31,86019 claims
PfizerEliquis, Paxlovid$187$22,62230 claims
Boehringer IngelheimJardiance$23$20,66418 claims
AstraZenecaFarxiga$67$17,36317 claims
AbbVieSynthroid$734$1,65915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in West Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →